REQUEST PRICE

Fields with * are required
Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Tachykinin 1/Substance P (NK1) Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Threonine338/Threonine339 phosphorylation of NK1 Receptor
pS338/pT339-NK1 (phospho-Tachykinin Receptor 1...
Threonine338/Threonine339 (T338/T339) is a major phosphorylation site of the NK1 receptor. The pT338/pT339-NK1 antibody detects phosphorylation in response to high-efficacy agonists. T338/T339 phosphorylation is a key regulator of NK1...
$ 350.00
NEW
Agonist-induced Threonine356/Threonine357 phosphorylation of NK1 Receptor
pT356/pT357-NK1 (phospho-Tachykinin Receptor 1...
Threonine356/Threonine357 (T356/T357) is a major phosphorylation site of the NK1 receptor. The pT356/pT357-NK1 antibody detects phosphorylation in response to high-efficacy agonists. T356/T357 phosphorylation is a key regulator of NK1...
$ 350.00
Citations
NK1 (non-phospho), Tachykinin Receptor 1/Substance P Receptor Antibody
NK1 (non-phospho), Tachykinin Receptor...
The NK1 antibody is directed against the distal end of the carboxyl-terminal tail of human Neurokinin Receptor 1 (also called Substance P Receptor). It detects selectively the canonical full-length NK1 Tachykinin Receptor. It can be used...
$ 350.00
NEW
pT344/pS347-NK1 (phospho-Tachykinin Receptor 1 Antibody)
pT344/pS347-NK1 (phospho-Tachykinin Receptor 1...
Threonine344/Serine347 (T344/S347) is a major phosphorylation site of the NK1 receptor. The pT344/pS347-NK1 antibody detects phosphorylation in response to high-efficacy agonists. T344/S347 phosphorylation is a key regulator of NK1...
$ 350.00

NK1

Tachykinin 1 (NK1) receptor is a member of the tachykinin receptor family, which is characterized by the ability to bind tachykinin neuropeptides resulting in spasmodic contractions. Substance P (SP) is the most selective agonist towards NK1. The NK1 receptor is a 7TM receptor that associates with the G-protein q11. NK1 is widely distributed in both the central nervous system and peripheral tissues including the substantia nigra, the hypothalamus, the lateral habenula, the inferior colliculus the central amygdala, the frontal cortex and the sensorimotor cortex as well as the gastrointestinal tract. Antagonists such as aprepitant and fosaprepitant were approved for the prevention of nausea and vomiting associated with cancer chemotherapy. NK1 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal threonine344/serine347 (pT344/pS347-NK1).This nomenclature refers to the human NK1 receptor. This phosphorylation motif is highly conserved across species but corresponds to pT344/pS346/pS347-NK1 in mice and rats. For more information on NK1 pharmacology please refer to the IUPHAR database. For further reading refer to:

Barrett J, Canning B, Coulson J, Dombrowsky E, Douglas SD, Fong TM, Heyward CY, Leeman SE, Remeshwar P. Tachykinin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

Tachykinin 1 (NK1) receptor is a member of the tachykinin receptor family, which is characterized by the ability to bind tachykinin neuropeptides resulting in spasmodic contractions. Substance... read more »
Close window
Tachykinin 1/Substance P (NK1) Receptor Antibodies

NK1

Tachykinin 1 (NK1) receptor is a member of the tachykinin receptor family, which is characterized by the ability to bind tachykinin neuropeptides resulting in spasmodic contractions. Substance P (SP) is the most selective agonist towards NK1. The NK1 receptor is a 7TM receptor that associates with the G-protein q11. NK1 is widely distributed in both the central nervous system and peripheral tissues including the substantia nigra, the hypothalamus, the lateral habenula, the inferior colliculus the central amygdala, the frontal cortex and the sensorimotor cortex as well as the gastrointestinal tract. Antagonists such as aprepitant and fosaprepitant were approved for the prevention of nausea and vomiting associated with cancer chemotherapy. NK1 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal threonine344/serine347 (pT344/pS347-NK1).This nomenclature refers to the human NK1 receptor. This phosphorylation motif is highly conserved across species but corresponds to pT344/pS346/pS347-NK1 in mice and rats. For more information on NK1 pharmacology please refer to the IUPHAR database. For further reading refer to:

Barrett J, Canning B, Coulson J, Dombrowsky E, Douglas SD, Fong TM, Heyward CY, Leeman SE, Remeshwar P. Tachykinin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

Recently viewed